Published in Atherosclerosis on February 01, 1978
Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med (1988) 1.34
Serial measurement of circulating immune complexes in myocardial infarction. Br Heart J (1981) 0.81
Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease. J Clin Immunol (1999) 0.76
An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus. Immunology (1984) 0.75
Immunological aspects of atheroma: a review. J R Soc Med (1979) 0.75
Classes and subclasses of rat immunoglobulins: interaction with the complement system and with staphylococcal protein A. Immunochemistry (1978) 2.06
Comparative study on antibodies to human and bacterial 60 kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur J Clin Invest (2001) 1.66
The role of C3 in the immune response. Immunol Today (1991) 1.25
A marked drop in the incidence of the null allele of the B gene of the fourth component of complement (C4B*Q0) in elderly subjects: C4B*Q0 as a probable negative selection factor for survival. Hum Genet (1991) 1.08
Association of elevated serum heat-shock protein 70 concentration with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia: a case-control study. J Hum Hypertens (2006) 1.07
Immunogenicity of antigen complexed with antibody. I. Role of different isotypes. Immunology (1982) 1.03
Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes. Clin Immunol Immunopathol (1976) 1.01
HIV and human complement: mechanisms of interaction and biological implication. Immunol Today (1993) 1.01
Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1. Immunology (1978) 0.98
The effect of immune complex composition on complement activation and complement dependent complex release. Immunochemistry (1978) 0.97
Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability. Int Immunol (1999) 0.97
Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol (2001) 0.97
High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol (2002) 0.97
Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV-1. Mol Immunol (1997) 0.96
Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology (1981) 0.96
The heterogeneity of Fc receptors on human peripheral mononuclear blood cells. Immunology (1979) 0.96
Interaction of C3 and C3b with immunoglobulin G. Mol Immunol (1983) 0.95
Effect of angiotensin II on macrophage functions. Immunology (1983) 0.94
Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41. Clin Exp Immunol (1993) 0.94
Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. AIDS (1997) 0.93
Effect of soluble immune complexes of Fc and C3 receptor-dependent phagocytosis by human monocytes. Immunology (1981) 0.92
Evaluation of different methods for detecting circulating immune complexes. An inter-laboratory study. J Immunol Methods (1980) 0.92
Immunological alterations in anti-HTLV-III negative haemophiliacs and homosexual men in Hungary. Immunol Lett (1985) 0.91
Isolation and characterization of Fc-receptors shed from human peripheral mononuclear cells. Immunology (1978) 0.91
Anti-Escherichia coli alpha-hemolysin in control and patient sera. Lancet (1982) 0.91
Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS (1991) 0.91
Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet (2001) 0.90
Activation of the complement system during infections due to gram-negative bacteria. Clin Immunol Immunopathol (1976) 0.90
Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. AIDS (1999) 0.89
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. J Med Genet (2002) 0.89
Association between early onset and organ manifestations of systemic lupus erythematosus (SLE) and a down-regulating promoter polymorphism in the MBL2 gene. Clin Immunol (2007) 0.88
Association of the GABRD gene and childhood-onset mood disorders. Genes Brain Behav (2010) 0.88
Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Z Gastroenterol (1999) 0.88
Smoking and a complement gene polymorphism interact in promoting cardiovascular disease morbidity and mortality. Clin Exp Immunol (2007) 0.87
The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg (1999) 0.87
Plasma high density lipoproteins in coronary, cerebral and peripheral vascular disease. The influence of various risk factors. Atherosclerosis (1982) 0.86
Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol (1995) 0.86
A 60 kD heat-shock protein-like molecule interacts with the HIV transmembrane glycoprotein gp41. Mol Immunol (1999) 0.86
Haemolytic uraemic syndrome and alpha-haemolytic Escherichia coli. Lancet (1984) 0.86
Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf) (2004) 0.86
Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun (2004) 0.85
Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol (1985) 0.85
Usefulness of densitometry in typing of human complement component C4. Immunogenetics (1989) 0.85
Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases. Stroke (2000) 0.84
Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody. AIDS (1992) 0.84
High level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. Immunobiology (2001) 0.84
The severity of clinical symptoms in ragweed-allergic patients is related to the extent of ragweed-induced complement activation in their sera. Allergy (1997) 0.84
BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology (1988) 0.84
The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. Clin Chim Acta (2001) 0.84
Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett (2001) 0.84
FN-C1q and C1 INH C1r-C1s complexes as indicators of complement activation in patients with chronic lymphocytic leukaemia. Immunol Lett (1989) 0.84
Evidences proving the intercalation hypothesis of the C-mediated complex release activity (CRA). Immunochemistry (1978) 0.84
Inhibition of the complement activation by an adrenal androgen, dehydroepiandrosterone. Complement (1984) 0.83
Angiooedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vasculitis. Acta Derm Venereol (2001) 0.83
Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology (1995) 0.83
Studies on the mechanism of the complement-mediated inhibition of the Fc and C3 receptors of B lymphocytes. Clin Immunol Immunopathol (1977) 0.83
Safety aspects of intravenous immunoglobulins. Immunol Invest (1988) 0.83
Study of the immune complex precipitation-inhibiting capacity of sera of patients with chronic lymphocytic leukaemia. Diagn Clin Immunol (1987) 0.83
Study of the interaction between monoclonal IgM proteins and the complement system. Immunochemistry (1976) 0.83
Free and complexed anti-lipoprotein antibodies in vascular diseases. Atherosclerosis (1983) 0.83
C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett (1987) 0.83
Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp Immunol (2012) 0.83
Changes induced by vascular antigens in the aorta of guinea-pigs: immunological and morphological studies. Br J Exp Pathol (1978) 0.83
Regulation of Fc mu receptor-mediated functions of resident and provoked peritoneal macrophages. Immunobiology (1984) 0.83
Coincidence of hereditary angioedema (HAE) with Crohn's disease. Immunol Invest (1999) 0.82
Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b. Immunol Lett (2000) 0.82
Danazol therapy for hereditary angio-oedema in children. Lancet (1999) 0.82
Antibodies against different epitopes of heat-shock protein 60 in children with type 1 diabetes mellitus. Immunol Lett (2002) 0.82
Th1 and Th2 cell responses of type 1 diabetes patients and healthy controls to human heat-shock protein 60 peptides AA437-460 and AA394-408. Inflamm Res (2005) 0.82
Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest (1998) 0.82
The control of cardiolipin and lecithin products with the 50 percent hemolysis method. Z Immunitatsforsch Allerg Klin Immunol (1968) 0.82
Activation of the classical complement pathway by homogeneous anti-SIII antibody bound to bivalent or trivalent oligosaccharide antigens. Mol Immunol (1979) 0.82
Mannan-binding lectin serum concentrations in HIV-infected patients are influenced by the stage of disease. Immunol Lett (1997) 0.81
Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand J Immunol (1995) 0.81
Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin Exp Immunol (2013) 0.81
Evaluation of different methods for detecting circulating immune complexes. Studies in patients with lung cancer. J Immunol Methods (1981) 0.81
Complement activating antibodies against the human 60 kDa heat shock protein as a new independent family risk factor of coronary heart disease. Eur J Clin Invest (2002) 0.81
Human anti-60 kD heat shock protein autoantibodies are characterized by basic features of natural autoantibodies. Acta Physiol Hung (2010) 0.81
Serial measurement of circulating immune complexes in myocardial infarction. Br Heart J (1981) 0.81
High prevalence of IgG and IgA antibodies to 19-kDa Helicobacter pylori-associated lipoprotein in chronic urticaria. Allergy (2003) 0.80
Interactions of radio-detoxified Escherichia coli endotoxin preparations with the complement system. Infect Immun (1977) 0.80
Acquired angioedema associated with chronic hepatitis C. J Allergy Clin Immunol (1999) 0.80
Usefulness of detection of complement activation products in evaluating SLE activity. Lupus (2000) 0.80
Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis (2001) 0.80
Complement activation in the nasal mucosa following nasal ragweed-allergen challenge. Pediatr Allergy Immunol (2001) 0.80
Appearance of covalently bound antigen in immune complexes formed during the activation of complement. J Immunol Methods (1984) 0.80
C1-inhibitor autoantibodies in SLE. Lupus (2010) 0.79
Patients with CLL and hypocomplementaemia have an impaired serum bactericidal activity against the Salmonella minnesota Re mutant. Complement (1988) 0.79
Increased frequency of the C3*F allele and the Leiden mutation of coagulation factor V in patients with severe coronary heart disease who survived myocardial infarction. Exp Clin Immunogenet (2001) 0.79
Depressed activation of the lectin pathway of complement in hereditary angioedema. Clin Exp Immunol (2008) 0.79
[Nasolith removal with ultrasound lithotripsy]. HNO (1991) 0.79
Comparative study of the complement-activating and specific IgE-binding properties of ragweed pollen allergen. Clin Exp Immunol (1997) 0.79
Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. Clin Immunol (2001) 0.79